CoChat

Comparison of insulin degludec with insulin glargine in insulin‐naive subjects with Type 2 diabetes: a 2‐year randomized, treat‐to‐target trial

Open access
Rodbard, H. W., Cariou, B., Zinman, B., Handelsman, Y., Philis‐Tsimikas, A., Skjøth, T. V., Rana, A., Mathieu, C., The BEGIN Once Long Trial Investigators · 2013 · Diabetic Medicine
Cited by 89

The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.

Abstract

Aims: The aim of this study was to compare long‐term safety and efficacy of the basal insulin analogue degludec with glargine in insulin‐naive subjects with Type 2 diabetes. Methods: This open‐label trial included a 52‐week core period followed by a 52‐week extension. Participants were randomized 3:1 to once‐daily degludec or glargine, administered with metformin ± dipeptidyl peptidase‐4 inhibitors. Basal insulin was titrated to target pre‐breakfast plasma glucose 3.9–4.9 mmol/l. Results: At end of treatment (104 weeks), mean HbA 1c reductions were similar for degludec and glargine; estimated treatment difference between degludec and glargine was 1 mmol/mol (95% CI −1 to 3) [0.07% (95% CI −0.07 to 0.22)], P = 0.339 in the extension trial set (degludec 551, glargine 174), comprising subjects who completed core trial and continued into the extension trial. Overall confirmed hypoglycaemia rates (1.72 vs. 2.05 episodes/patient‐year), rates of adverse events possibly or probably related to trial product (0.19 events/patient‐year), weight gain (2.7 vs. 2.4 kg) and mean daily insulin doses (0.63 U/kg) were similar between treatments in the safety analysis set (degludec 766, glargine 257) comprising all treated subjects. Rates of nocturnal confirmed hypoglycaemia (0.27 vs. 0.46 episodes/patient‐year; P = 0.002) and severe hypoglycaemia (0.006 vs. 0.021 episodes/patient‐year, P = 0.023) were significantly lower with degludec for the safety analysis set (analysis based on intention‐to‐treat full analysis set comprising all randomized subjects). Conclusions: In Type 2 diabetes, insulin degludec in combination with oral anti‐diabetic drugs, safely and effectively improves long‐term glycaemic control, with a significantly lower risk of nocturnal hypoglycaemia as compared with glargine.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/dme.12303

Cites

6 of 6 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Cited by

See all 89

Metadata

Authors
Rodbard, H. W., Cariou, B., Zinman, B., Handelsman, Y., Philis‐Tsimikas, A., Skjøth, T. V., Rana, A., Mathieu, C., & The BEGIN Once Long Trial Investigators
Venue
Diabetic Medicine
Publisher
Wiley
Published
2013-09-30
Volume
30
Issue
11
Pages
1298-1304
ISSN
  • 0742-3071 (ISSN-L)
  • 1464-5491
OpenAlex
W1981378897
Cited by
89
References
6
FWCI
9.91
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.